Roundtable Discussion: IsoPlexis’ Single-Cell Proteomics Accelerates Innovations in Cancer Immunology Research

Leading Researchers Discuss New Therapeutics & How Functional Proteomics Addresses Gaps in Cancer Research

GEN Eng News recently held a roundtable discussion with several leading cancer immunology researchers to discuss some of the challenges and advancements in the field. Tumor heterogeneity, access to the tumor microenvironment, and technological gaps were highlighted as underlying challenges in the field. The leading researchers also discussed advancements in single-cell functional analysis, especially to more deeply analyze blood, as the future of cancer immunology research. The ability to obtain information on tumor T cells from the blood rather than the tumor itself, which is more difficult to access, would allow treatments to be tailored to the patient more easily. The researchers emphasized how far the field of cancer immunology has come in recent years, and how current challenges motivate cutting-edge developments in cancer research technology. IsoPlexis’ single-cell proteomics has been used to accelerate research and translational insights in the cancer immunology field and published in a wide variety of high impact publications, some of which are highlighted in the literature review included with this roundtable.

Dr. James R. Heath of the Institute for Systems Biology, Dr. Naval Daver of MD Anderson Cancer Center, Dr. Taha Merghoub of Memorial Sloan Kettering Cancer Center, and Dr. Lisa Butterfield of the Parker Institute for Cancer Immunotherapy and University of California, San Francisco joined moderator Dr. Julianna LeMieux of GEN News in a discussion of key issues and advancements in cancer immunology.

Topics discussed in this roundtable include:

  • What are the limitations of the current standard methods for evaluating the mechanisms related to persistence, suppression, and resistance within the tumor-immune interactions with patients?
  • How do single-cell solutions address gaps in the current biomarker offerings?
  • What are the novel strategies being used to overcome challenges such as antigen escape?
  • Given the complexity of the tumor microenvironment, how does understanding the function of different cell types involved in the immune response help accelerate the development of novel therapies?

Read the full Cancer Immunology Roundtable now.

Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.